154 related articles for article (PubMed ID: 37700916)
1. The Effect Of Continuously Dutasteride Monotherapy on The Expression Of Protein Kinase C-Alpha Enzyme In BPH Model Of Wistar Strain Rattus Novergicus Rat.
Daryanto B; Suharibawa IGLA; Purnomo AF; Nurhadi P; Wardhani V
Med Arch; 2023; 77(3):202-206. PubMed ID: 37700916
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Tamsulosin, Dutasteride Monotherapy and Tamsulosin-Dutasteride Combination on Prostate Smooth Muscle Contractility in BPH Model Wistar Strain Rattus Novergicus.
Daryanto B; Naim HY; Budaya TN
Med Arch; 2023 Feb; 77(1):13-17. PubMed ID: 36919125
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Long-Term Tamsulosin Monotherapy and Tamsulosin - Dutasteride Combination Therapy on PKC-α Enzyme Expression in Prostate Stromal Tissue.
Daryanto B; Purnomo AF; Patriawan YS; Purnomo BB
Med Arch; 2023; 77(6):446-450. PubMed ID: 38313112
[TBL] [Abstract][Full Text] [Related]
4. Linh Phu Khang Tue Tinh inhibited prostate proliferation in rats induced benign prostatic hyperplasia by testosterone propionate.
Minh TD; Thanh Ha TN; Duy TN; Hoang NN; PhamTien D; Thai HP; Thi HN; Thi Lan PD; Quoc BP; Ivkin DY; Povydysh MN; Cong BN; Krasnova MV
J Ethnopharmacol; 2021 Oct; 279():114388. PubMed ID: 34224813
[TBL] [Abstract][Full Text] [Related]
5. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
6. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
[TBL] [Abstract][Full Text] [Related]
7. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
8. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
9. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
[TBL] [Abstract][Full Text] [Related]
10. Dutasteride: a review of its use in the management of prostate disorders.
Keam SJ; Scott LJ
Drugs; 2008; 68(4):463-85. PubMed ID: 18318566
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.
Miller J; Tarter TH
Clin Interv Aging; 2009; 4():251-8. PubMed ID: 19554096
[TBL] [Abstract][Full Text] [Related]
13. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
14. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
[TBL] [Abstract][Full Text] [Related]
15. Dutasteride for the treatment of benign prostatic hyperplasia.
Wu C; Kapoor A
Expert Opin Pharmacother; 2013 Jul; 14(10):1399-408. PubMed ID: 23750593
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia--The Markov model based on data from Montenegro.
Dabanović V; Kostić M; Janković S
Vojnosanit Pregl; 2016 Jan; 73(1):26-33. PubMed ID: 26964381
[TBL] [Abstract][Full Text] [Related]
17. Effects of the dutasteride and sildenafil association in the penis of a benign prostatic hyperplasia animal model.
Da Silva MHA; Medeiros JL; Costa WS; Sampaio FJB; De Souza DB
Aging Male; 2020 Dec; 23(5):1009-1015. PubMed ID: 31429633
[TBL] [Abstract][Full Text] [Related]
18. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
19. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
20. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
Traish A; Haider KS; Doros G; Haider A
Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
